Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Increase in Short Interest

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) saw a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 67,700 shares, a growth of 67.6% from the November 30th total of 40,400 shares. Currently, 5.1% of the shares of the company are short sold. Based on an average daily volume of 311,300 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC bought a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. Institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Stock Performance

Shares of NASDAQ SNOA remained flat at $2.75 during midday trading on Friday. The stock had a trading volume of 39,072 shares, compared to its average volume of 208,409. Sonoma Pharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $9.37. The stock has a market cap of $3.68 million, a price-to-earnings ratio of -0.55 and a beta of 1.43. The business’s fifty day moving average is $2.79 and its 200 day moving average is $1.87.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.